Juve Stabia’s squad value has risen 245%, from $9.3M to $32.3M over the 2024-25 season, as the team climbed to 5th place in Italy’s Serie B final football standings Juve Stabia’s squad value has risen 245%, from $9.3M to $32.3M over the 2024-25 season, as the team climbed to 5th place in Italy’s Serie B final football standings Juve Stabia’s squad value has risen 245%, from $9.3M to $32.3M over the 2024-25 season, as the team climbed to 5th place in Italy’s Serie B final football standings Dublin, Irel ...

100mm Cigarettes Comprise Approximately Half the U.S. Market, Giving Even More Smokers a Familiar Choice as They Seek Ways to Change Their Smoking Behavior First FDA Submission Planned for Q4 2025 MOCKSVILLE, N.C.,, June 26, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced the advancement of a 100mm VLN® reduced nicotine content cigarett ...

American Rebel Holdings Inc American Rebel Light Beer Online Orders Soar as American Rebel Beer Ships to Over 40 States; Free Shipping Available Through June 30 NASHVILLE, TN, June 26, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel, proudly reports explosive online sales grow ...

JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) ...

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile Full study data from both cohorts expected later this year BARCELONA, Spain, June 26, 2025 (GLOBE NEWSWIRE) -- The Australasian Gastro-In ...

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects ZORYVE’s proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitorAmong newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis in AAD’s focuse ...

VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, announces it has signed an offer to acquire a well-established North Carolina-based land surveying company with a strong government customer base. The proposed acquisition expands operations in the state when combined with a previously announced proposed land surve ...

LOS ANGELES, June 26, 2025 (GLOBE NEWSWIRE) -- LiveOne (Nasdaq: LVO), an award-winning, creator-first, music, entertainment, and technology platform, announced today that it will be hosting a conference call on Thursday July 3, 2025, to discuss results for the fourth fiscal quarter ("Q4 Fiscal 2025”) and fiscal year ended March 31, 2025 ("Fiscal 2025") and provide a business update. To access the call, please use the following information: Q4 Fiscal 2025 and Fiscal 2025 Earnings Conference CallDate:Thursday ...

The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated 6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compl ...

Cerence core tech supports agentic voice assistant experience, rolling out first in the automaker’s latest addition to its electric vehicle lineupBURLINGTON, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that its core technologies are supporting new agentic and generative AI capabilities in the next-generation of MBUX, rolling out first in the all-new and all-electric Mercedes-Benz C ...